Asthma is the most common chronic disease in children, imposing a consistent burden on health system. In recent years, prevalence of asthma symptoms became globally increased in children and adolescents, particularly in Low-Middle Income Countries (LMICs). Host (genetics, atopy) and environmental fa...ctors (microbial exposure, exposure to passive smoking and air pollution), seemed to contribute to this trend. The increased prevalence observed in metropolitan areas with respect to rural ones and, overall, in industrialized countries, highlighted the role of air pollution in asthma inception. Asthma accounts for 1.1% of the overall global estimate of “Disability-adjusted life years” (DALYs)/100,000 for all causes. Mortality in children is low and it decreased across Europe over recent years. Children from LMICs particularly suffer a disproportionately higher burden in terms of morbidity and mortality. Global asthma-related costs are high and are usually are classified into direct, indirect and intangible costs. Direct costs account for 50–80% of the total costs. Asthma is one of the main causes of hospitalization which are particularly common in children aged < 5 years with a prevalence that has been increased during the last two decades, mostly in LMICs. Indirect costs are usually higher than in older patients, including both school and work-related losses. Intangible costs are unquantifiable, since they are related to impairment of quality of life, limitation of physical activities and study performance. The implementation of strategies aimed at early detect asthma thus providing access to the proper treatment has been shown to effectively reduce the burden of the disease.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Guide d’urgence provisoire
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... the WHO and the PAHO recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications
more
إن حول الإصدارات الإعلامية للنتائج الأولية للتجربة الإكلينيكية العشوائية ٍّتام) والتي تضمنت ديكساميثازون على إدراك Africa CDC المركز الأفريقي لمكافحة الأمراض و الوقاي...ة منها، UKالكبيرة التي أجريت في المملكة المتحدة () أفاد الباحثون بأن إعطاء ديكساميثازون ۱وكورتيكوستيرويد كإحدى أذرع العلاج.(عن طريق الفم أو عن طريق الحقن أدى إلى انخفاض حوالي ثلث الوفيات بين الذين يحتاجون إلى i]COVID-19المرضى المصابين بفيروس كورونا المستجد [َّتهوية ميكانيكية وحوالي الخمس للمرضى الذين يحتاجون إلى الأكسجين. إنا مدرج في قائمة الأدوية الأساسية ًديكساميثازون هو دواء عام وغير مكلف نسبيإفريقيا.لمنظمة الصحة العالمية ويستخدم على نطاق واسع في
more
It is Zika virus (ZIKV) that most often causes these neurological effects it appears to be the only arbovirus than can cause congenital malformations such as microcephaly. In any case, more scientific tests are needed to establish the causal relationship between the virus and this malformation (7-10...).
This document is a practical tool designed to help health workers improve clinical diagnosis and provide timely care for patients infected
with the dengue, chikungunya, or Zika virus. It is intended mainly for
health workers in primary care facilities where laboratory diagnosis of
arboviruses is not always available. However, this guide may also be
very useful in hospitals that provide second- and third-level care, as it
describes the clinical manifestations of each of the three most important
arboviral diseases currently found in the Region, the elements for
differential diagnosis, and their clinical behavior.
more
Ces lignes directrices prônent une approche centrée sur la personne des informations stratégiques sur le VIH, ce qui implique de cesser de collecter des données agrégées dans les services (par exemple, le nombre de tests de dépistage du VIH administrés) pour s’intéresser au patient qui re...çoit une cascade de services liés entre eux, afin d’améliorer les soins prodigués aux patients et les résultats sanitaires.
Elles réunissent les orientations données en matière de systèmes de suivi des patients et de cas d’infection à VIH dans le cadre du système de surveillance de santé publique. Elles recommandent le recours à un identifiant unique pour le patient, afin d'établir une liaison entre tous les services de santé, ce qui permet de mesurer la cascade de services sur la durée.
more
KNCV Tuberculosis Foundation - Your partner in the fight against TB
Accessed November 2017
Each year, ≈795 000 individuals in the United States experience a stroke, of which 87% (690 000) are ischemic and 185 000 are recurrent.1 Approximately 240 000 individuals experience a transient ischemic attack (TIA) each year.2 The risk of recurrent stroke or TIA is high but can be mitiga...ted with appropriate secondary stroke prevention. In fact, cohort studies have shown a reduction in recurrent stroke and TIA rates in recent years as secondary stroke prevention strategies have improved.3,4 A meta-analysis of randomized controlled trials (RCTs) of secondary stroke prevention therapies published from 1960 to 2009 showed a reduction in annual stroke recurrence from 8.7% in the 1960s to 5.0% in the 2000s, with the reduction driven largely by improved blood pressure (BP) control and use of antiplatelet therapy.5 The changes may have been influenced by changes in diagnostic criteria and differing sensitivities of diagnostic tests over the years.
more
Indian J Psychiatry. 2012 Jan-Mar; 54(1): 41–47.
doi: 10.4103/0019-5545.94644
Mycetoma is a slow-growing bacterial or fungal infection, most often of the foot, that may spread to other parts of the body and can cause severe deformity. It is a debilitating disease that most often affects poor people in rural areas with limited access to health care.
Brochure about high blood pressure for patients